Disease modifying treatments for Parkinson’s disease – an update

Abstract

An improved understanding of the pathological processes leading to neurodegeneration in Parkinson’s disease (PD) is leading to the development of a number of disease modifying agents. These include both novel and repurposed drugs. Some of these disease modifying therapies act on cellular targets that have been identified by genetic mutations, while others act on other cellular process which we know are affected in PD. This review provides an update on the progress in the field, and highlights some areas of special interest.